SGEN : Summary for Seattle Genetics, Inc. - Yahoo Finance

We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

Seattle Genetics, Inc. (SGEN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
64.87 -2.06 (-3.08%)
At close: 4:00 PM EST
People also watch :
IMGN BMRN INCY ALNY MDVN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close 66.93
Open 67.46
Bid 63.90 x 1500
Ask 67.86 x 100
Day's Range 64.81 - 68.68
52 Week Range 26.02 - 75.36
Volume 697,714
Avg. Volume 1,195,929
Market Cap 9.18B
Beta 2.33
PE Ratio (TTM) -82.85
EPS (TTM) -0.78
Earnings Date Feb 7, 2017 - Feb 13, 2017
Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 56.43
Trade prices are not sourced from all markets
  • Why Seattle Genetics Stock Surged Higher in November
    Motley Fool yesterday

    Why Seattle Genetics Stock Surged Higher in November

    Seattle Genetics got a boost from Donald Trump's underdog victory last month.

  • Capital Cube 8 days ago

    ETFs with exposure to Seattle Genetics, Inc. : December 2, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Seattle Genetics, Inc. Here are 5 ETFs with the largest exposure to SGEN-US. Comparing the performance and risk of Seattle Genetics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC
    Investor's Business Daily 9 days ago

    Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC

    Biotech stocks will likely close 2016 down by double digits, but 2017 is filled with catalysts, RBC analyst Adnan Butt says.

  • Hedge Funds Are Coming Back to Seattle Genetics, Inc. (SGEN)
    Insider Monkey 9 days ago

    Hedge Funds Are Coming Back to Seattle Genetics, Inc. (SGEN)

    Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]

  • Barrons.com 9 days ago

    [$$] Three Biotechs With Bullish Insider Buying

    Biotech investors Felix and Julian Baker paid more than $150 million to increase their holdings in three companies in November. The purchases are impressively bullish as the Bakers are already the largest beneficial holders of Seattle Genetics (SGEN), BeiGene (BGNE) and Invitae (NVTA). Entities controlled by the Bakers bought 1,611,562 shares of Seattle Genetics for $91.8 million, about $56.93 a share, from Nov. 1 through 8 on the open market, regulatory filings show.

  • Barrons.com 25 days ago

    [$$] Biotech M&A Could Surge Under Trump

    Credit Suisse Our small- to midcap biotech coverage universe ended the week up 29%, but remains down 14% year-to-date. The biotech sector rallied this past week on the back of Donald Trump’s Presidential ...

  • Could Trump 'Make Drug Development Great Again'?
    Investor's Business Daily 26 days ago

    Could Trump 'Make Drug Development Great Again'?

    Donald Trump will likely seek faster drug pipelines, buoying Medidata Solutions, KeyBanc analyst Donald Hooker said Monday.

  • Incyte Corporation (INCY), Seattle Genetics, Inc. (SGEN) & Two More: Top Healthcare Hedge Fund Loves These Stocks
    Insider Monkey 26 days ago

    Incyte Corporation (INCY), Seattle Genetics, Inc. (SGEN) & Two More: Top Healthcare Hedge Fund Loves These Stocks

    Baker Bros. Advisors is a fund managed by Julian Baker and Felix Baker that mainly invests in biotechnology companies, and today we are going to take a closer look at four of its favorite health picks, including Incyte Corporation (NASDAQ:INCY), Seattle Genetics, Inc. (NASDAQ:SGEN), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), and ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). At the end of […]

  • 24/7 Wall St. 27 days ago

    Massive Icahn Trades Highlight Huge Insider Buying: Hertz Global, Herbalife, CBRE, Seattle Genetics and More

    After a dramatic conclusion to the presidential race, insider buying was dramatically larger than we have seen in months, and it could continue the rest of the year.

  • American City Business Journals 29 days ago

    Seattle Genetics moves up FDA timeline for cash cow drug Adcetris

    Seattle Genetics will be ready to seek Food and Drug Administration approval for its most important and potentially most lucrative drug sooner than expected, its top executive said. Seattle Genetics has been testing its flagship Adcetris drug as a first line of treatment for patients with advanced lymphoma instead of as a last resort for the cancer, which is currently the drug's only FDA-approved application. CEO Clay Siegall said he expects final results from the Echelon-1 trial in 2017, rather than as late as mid 2018.